Tuberculosis remains a significant health challenge, affecting approximately 2.5 billion people annually in India alone. During treatment, a notable percentage of patients, ranging from 3% to 35%, develop multidrug-resistant tuberculosis (MDR-TB), which is notoriously difficult to treat. Factors such as diabetes, HIV, malnutrition, stress, smoking, depression, and certain genetic mechanisms can impair drug absorption and bioavailability, thereby increasing the likelihood of MDR-TB. This resistance contributes to higher death and relapse rates.

To combat this, it is essential to monitor drug levels at the onset of treatment. This approach enables the personalization of TB treatment regimens, potentially leading to more complete recoveries. However, current methods for plasma drug level estimation, such as Liquid Chromatography Mass Spectrometry (LCMS) and High-Pressure Liquid Chromatography (HPLC), are costly, require specialized expertise, and necessitate significant plasma volumes (around 3 ml), limiting their practicality and accessibility.

Innovative Solution: AkshaisarathiVig

Our groundbreaking product, “AkshaisarathiVig,” revolutionizes the way we monitor essential TB medication levels. Designed with state-of-the-art microfluidics and nanotechnology, this device provides several transformative advantages:

• Bedside Convenience: Performs drug level estimations directly at the patient’s bedside, eliminating the need for complex lab procedures.
• Cost-Effective: Offers a more affordable solution, ensuring wider accessibility and frequent monitoring capabilities.
• Minimal Sample Requirement: Utilizes only microliters of plasma, far less than traditional methods, facilitating easier and more comfortable sampling.
• Rapid and Accurate: Delivers timely and precise assessments, crucial for effective treatment adjustments.

With AkshaisarathiVig 2 measuring levels of Isoniazid and Rifampicin/Isoniazid, and AkshaisarathiVig 4 focusing on Rifampicin/Ethambutol-Ethambutol/Pyrazinamide, these tools are tailored to address the specific needs of TB treatment in diverse patient populations.

Our commitment to innovation in TB treatment monitoring with AkshaisarathiVig aims to drastically reduce the burden of multidrug resistance, ensuring that every patient has the best possible chance at recovery.